Patients with severe atopic dermatitis, defined as a score of 8-9 on the Rajka and Langeland criteria who are unresponsive, intolerant or contra-indicated to cyclisporin treatment. MedDRA version: 9.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis
Conditions
Interventions
Trade Name: Methotrexaat 2,5 PCH, tabletten 2,5 mg
Product Name: Methotrexaat
Pharmaceutical Form: Tablet
Trade Name: Azathioprine
Product Name: Azathioprine
Pharmaceutical Form: Tablet
Sponsors
Academic Medical Center, Department of dermatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subject is 18 years of age or older at inclusion (Day 0); both genders. 2. Subject has a diagnosis of AD based on millennium criteria (with or without IgE) and UK-criteria. 3. Subject has a score of 8-9 on the Rajka and Langeland Criteria which corresponds with a severity of ‘severe’. 4. Subject is unresponsive, intolerant or contra-indicated to cyclosporin treatment. 5. Female subject is either not of childbearing potential, defined as postmenopausal or surgically sterile or is of childbearing potential and practicing one of the following methods of birth control throughout the study until 3 months after receiving the last study agent: - sponge, foams, jellies, diaphragm or intrauterine device (IUD) - Contraceptives (oral, parenteral, patch) for three months prior to study drug administration. - A vasectomized partner 6. Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test at Baseline. 7. Sexually active male subjects are able to participate in the study if they use effective contraception during the study and 3 months after discontinuation of the study drug. 8. Have screening laboratory test results within reference values or results without clinical relevance as assessed by the local investigator. 9. Subjects has voluntarily signed and dated an informed consent prior to any study related procedure and is willing to comply with the requirements of this study protocol which has been approved by an Institutional Review Board (IRB/Independent Ethics Committee (IEC)). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Subjects is pregnant, nursing, or planning pregnancy (men and women) while enrolled in the study. 2. Subjects has used any investigational drug within the previous 4 weeks or 5 times the half-life of the investigational agent prior to the first administration of study agent, whichever is longer. 3. Subject has ever used azathioprine or methotrexate before 4. Subject has received phototherapy or any systemic medications/treatments that could affect AD evaluation (including, but not limited to, oral or injectable corticosteroids) within the last 4 weeks of the first administration of study agent. 5. Subject has used very potent topical medications/treatments that could affect AD evaluation within 2 weeks of the first administration of study agent. 6. A history of chronic or recurrent infectious diseases, including but not limited to chronic renal infection, chronic chest infection (eg, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), or open, draining, or infected skin wounds or ulcers. 7. A history of alcohol abuse 8. A history of latent or active granulomatous infection, including TB, histoplasmosis, or coccodioidomycosis, prior to screening. 9. Subject has or had had herpes zoster infection within 2 months of study day 0. 10. Subject is known to be infected with HIV, hepatitis B, or hepatitis C. 11. A history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease. 12. Subject has a transplanted organ (with exception of a corneal transplant > 3 months prior to the first administration of study agent). 13. A history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly. 14. Subject has any known malignancy or had a history of malignancy. 15. Subject has undergone allergy immunotherapy previously for prevention of anaphylactic reactions. 16. Subject participates in another trial using an investigational agent or procedure during participation in the trial. 17. Subject is dependant of a concomitant medication that has interaction with the study medication and thereby should be avoided.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the efficacy of methotrexate versus azathiorpine treatment in adult patients with chronic severe AD. ;Secondary Objective: • Safety and tolerability • The effect of therapy on quality of life. ;Primary end point(s): The primary efficacy variables are the SCORAD and Investigators Global Assessment response at week 12. | — |
Countries
Netherlands
Outcome results
None listed